7th May 2025 09:33
(Alliance News) - AstraZeneca PLC on Wednesday said it has received positive high-level results from its latest trial evaluating Enhertu in patients with high-risk, locally advanced HER2-positive early-stage breast cancer.
The Cambridge-based pharmaceuticals company said the Destiny-Breast11 phase 3 trial showed Enhertu, or trastuzumab deruxtecan, followed by paclitaxel, trastuzumab and pertuzumab demonstrated a statistically and clinically meaningful improvement in pathologic complete response rate compared with the current standard of care.
Enhurtu is being jointly developed and commercialised by AstraZeneca and Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd.
Around one in three patients with early-stage breast cancer are considered high risk, meaning they are more likely to experience disease recurrence and have a poor prognosis.
The trial's secondary endpoint of event-free survival was not mature at the time of analysis, AstraZeneca explained, though noted that survival data showed an early positive trend compared to standard of care.
"The clinically meaningful improvement in pathologic complete response and the safety data seen in Destiny-Breast11 highlight the potential of Enhertu to challenge the current standard of care in early-stage HER2-positive breast cancer," said Susan Galbraith, AstraZeneca executive vice president, Oncology Haematology research & development.
"Enhertu is already an important treatment option in the metastatic setting, and these data have the potential to allow this medicine to move into early stages of disease where cure is possible."
Shares in AstraZeneca were down 1.9% at 10,498.00 pence each in London on Wednesday morning. The stock is down 13% over the past year.
Shares in Daiichi closed down Sankyo 3.2% at JPY3,583.00 in Tokyo.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca